scholarly journals Correlation of Scintigraphic Results Using123I-Methoxybenzamide with Hormone Levels and Tumor Size Response to Quinagolide in Patients with Pituitary Adenomas

1998 ◽  
Vol 83 (1) ◽  
pp. 248-252 ◽  
Author(s):  
Diego Ferone ◽  
Secondo Lastoria ◽  
Annamaria Colao ◽  
Paola Varrella ◽  
Gaetana Cerbone ◽  
...  
Keyword(s):  
Tumor Size ◽  
Pituitary Adenomas ◽  
Hormone Levels

scholarly journals Salvage therapy with temozolomide in patients with aggressive or metastatic pituitary adenomas: experience in six cases

2010 ◽  
Vol 163 (6) ◽  
pp. 843-851 ◽  
Author(s):  
Marco Losa ◽  
Elena Mazza ◽  
Maria Rosa Terreni ◽  
Ann McCormack ◽  
Anthony J Gill ◽  
...  
Keyword(s):  
Pituitary Adenoma ◽  
Tumor Size ◽  
Pituitary Adenomas ◽  
Dna Methyltransferase ◽  
Response Assessment ◽  
Pituitary Carcinoma ◽  
Consecutive Series ◽  
Positive Staining ◽  
Hormone Levels ◽  
Wide Range

ObjectiveThe prognosis of either pituitary carcinoma or aggressive pituitary adenoma resistant to standard therapies is poor. We assessed the efficacy of treatment with temozolomide, an oral second-generation alkylating agent, in a consecutive series of six patients with aggressive pituitary adenomas.DesignThis was a 1-year prospective study of temozolomide therapy in six consecutive patients with pituitary carcinoma (one case) or atypical pituitary adenoma (five cases) resistant to standard therapies. There were three males and three females. Age at enrollment ranged between 52 and 64 years. Temozolomide was given orally at a dose of 150–200 mg/m2 per day for 5 days every 4 weeks for a maximum of 12 cycles.MethodsResponse assessment was based on measurable change in tumor size, as assessed on magnetic resonance imaging, and hormone levels. Response was defined as reduction of at least 50% of tumor size and hormone levels.ResultsFour patients completed the 12 cycles of temozolomide treatment, as planned. Two patients stopped the drug after 3 and 6 months respectively because of the progression of disease. Two patients responded to temozolomide, while the remaining two patients had stable disease. Immunohistochemistry for O6-methylguanine-DNA methyltransferase (MGMT) in tumor sample showed a partial association with treatment response.ConclusionsTemozolomide treatment has a wide range of efficacy in patients with pituitary carcinoma or locally aggressive pituitary adenoma. Positive staining for MGMT seems likely to predict a lower chance of response.

scholarly journals The Expression of E-Cadherin in Somatotroph Pituitary Adenomas Is Related to Tumor Size, Invasiveness, and Somatostatin Analog Response

2010 ◽  
Vol 31 (2) ◽  
pp. 257-257
Author(s):  
Stine Lyngvi Fougner ◽  
Tove Lekva ◽  
Olivera Casar Borota ◽  
John K. Hald ◽  
Jens Bollerslev ◽  
...  
Keyword(s):  
Tumor Size ◽  
Pituitary Adenomas ◽  
Somatostatin Analog ◽  
E Cadherin

scholarly journals P13.01 TERTpromoter methylation is significantly associated withTERTupregulation and tumor progression in pituitary adenomas

2019 ◽  
Vol 21 (Supplement_3) ◽  
pp. iii62-iii62
Author(s):  
J Adachi ◽  
Y Miyake ◽  
T Suzuki ◽  
K Mishima ◽  
R Araki ◽  
...  
Keyword(s):  
Promoter Methylation ◽  
Tumor Size ◽  
Pituitary Adenomas ◽  
Tumor Recurrence ◽  
Methylation Status ◽  
Tumor Subtype ◽  
Resection Rate ◽  
Tert Promoter ◽  
Hotspot Mutations ◽  
Tert Expression

Abstract BACKGROUND Activation of telomerase plays a critical role in tumor development. Somatic alterations in the promoter of the telomerase reverse transcriptase (TERT) gene are a major mechanism of upregulating telomerase. Several mechanisms have been associated with TERT abnormalities, including TERT promoter mutations or methylation. Mutations in the TERT promoter have been observed in a subset of brain tumors, especially in adult gliomas. In pituitary adenomas (PAs), however, TERT abnormalities are not fully understood. The present study aimed to investigate not only mutational but also methylation status changes in the TERT promoter in PAs and to analyze their correlations with clinical variables. MATERIAL AND METHODS We retrospectively studied 70 PAs consisting of 53 primary and 17 recurrent samples. Clinical data, including age at surgery, sex, tumor size, tumor subtype, resection rate, presence or absence of postoperative irradiation, and progression-free survival (PFS), were obtained from medical records. First, we investigated TERT promoter hotspot mutations via Sanger sequencing. Next, we quantified the methylation status of the TERT promoter using methylation-sensitive high-resolution melting analysis (MS-HRM). Finally, we investigated TERT mRNA expression levels using real-time quantitative PCR. Fisher’s exact test was applied to evaluate the statistical significance between TERT promoter methylation status and tumor recurrence. PFS was calculated using Kaplan-Meier estimates and compared between methylated with ummethylated PAs with the log-rank test. The correlation between TERT promoter methylation status and mRNA levels was analyzed with the Mann-Whitney U-test. PFS was analyzed using multivariate analysis with the Cox proportional hazards model and included the following variables: age, sex, tumor size, tumor subtype, resection rate, radiation therapy, and methylation status. RESULTS TERT promoter hotspot mutations were not observed in any PA sample. Nineteen percent of PAs exhibitedTERT promoter methylation, which was significantly predominant in recurrent PA samples. PFS was significantly shorter in the methylated cases than in the unmethylated cases. Higher TERT expression levels were correlated with methylation status. CONCLUSION We found that TERT promoter methylation upregulated TERT expression and was associated with shorter PFS in PAs. Our results suggest thatTERT promoter methylation may be a potential biomarker for predicting tumor recurrence in PAs.

scholarly journals The Expression of E-Cadherin in Somatotroph Pituitary Adenomas Is Related to Tumor Size, Invasiveness, and Somatostatin Analog Response

2010 ◽  
Vol 24 (4) ◽  
pp. 874-875
Author(s):  
Stine Lyngvi Fougner ◽  
Tove Lekva ◽  
Olivera Casar Borota ◽  
John K. Hald ◽  
Jens Bollerslev ◽  
...  
Keyword(s):  
Tumor Size ◽  
Pituitary Adenomas ◽  
Somatostatin Analog ◽  
E Cadherin

scholarly journals Prevalence of Gs alpha mutations in Korean patients with pituitary adenomas

2001 ◽  
Vol 168 (2) ◽  
pp. 221-226 ◽  
Author(s):  
HJ Kim ◽  
MS Kim ◽  
YJ Park ◽  
SW Kim ◽  
DJ Park ◽  
...  
Keyword(s):  
Tumor Size ◽  
Pituitary Adenomas ◽  
Direct Sequencing ◽  
Point Mutations ◽  
Low Frequency ◽  
Oral Glucose ◽  
Fresh Tissue ◽  
Korean Patients ◽  
Gs Alpha ◽  
Non Functioning Pituitary Adenomas

The reported frequencies of Gs alpha mutations (gsp mutations) in growth hormone (GH)-secreting pituitary adenomas are variable (ranging from 4.4 to 43%), and the presence of these mutations in the other pituitary adenomas is still a matter of controversy. Previous clinical and biochemical analyses of patients with GH-secreting pituitary adenomas and gsp mutations produced conflicting results and did not demonstrate obvious characteristics. Therefore, we investigated the prevalence of gsp mutations in Korean patients with pituitary adenomas and elucidated the characteristics of these patients. Forty-four GH-secreting adenomas, 7 prolactin (PRL)-secreting adenomas and 32 clinically non-functioning adenomas were examined for the presence of point mutations in codon 201 and 227 of the Gs alpha gene using a nested PCR and direct sequencing of DNA extracted from fresh tissue or paraffin-embedded pituitary adenoma samples. Seven of the 44 GH-secreting pituitary adenomas had point mutations at codon 201 or 227; of these, five mutations were in codon 201 and two were in codon 227. In patients with gsp mutations, mean tumor size was significantly smaller than in patients without gsp mutations (15.9+/-8.7 mm vs. 24.9+/-14.9 mm, P<0.05). Age, sex, basal GH levels, GH response to oral glucose loading, GH response to octreotide and surgical outcome were not different in the two groups. One of the 32 clinically non-functioning pituitary adenomas had a point mutation at codon 201; none of the seven prolactinomas had these mutations. These results show that gsp mutations are not rare in Korean acromegalic patients and mean tumor size is significantly smaller in acromegalic patients with gsp mutations. Our results also confirm the low frequency of gsp mutations in clinically non-functioning pituitary adenomas and the absence of gsp mutations in prolactinoma.

scholarly journals Lack of correlation between Ki-67 labelling index and tumor size of anterior pituitary adenomas

BMC Cancer ◽  
2001 ◽  
Vol 1 (1) ◽  
Author(s):  
Luciano Mastronardi ◽  
Antonio Guiducci ◽  
Fabrizio Puzzilli
Keyword(s):  
Tumor Size ◽  
Pituitary Adenomas ◽  
Anterior Pituitary ◽  
Labelling Index ◽  
Ki 67

scholarly journals Correction to: Solid tumor size for prediction of recurrence in large and giant non-functioning pituitary adenomas

2021 ◽  
Author(s):  
Ching-Chung Ko ◽  
Chin-Hong Chang ◽  
Tai-Yuan Chen ◽  
Sher-Wei Lim ◽  
Te-Chang Wu ◽  
...  
Keyword(s):  
Solid Tumor ◽  
Tumor Size ◽  
Pituitary Adenomas ◽  
Non Functioning Pituitary Adenomas

Radiosurgery for growth hormone—producing pituitary adenomas

2000 ◽  
Vol 93 (supplement_3) ◽  
pp. 6-9 ◽  
Author(s):  
Nan Zhang ◽  
Li Pan ◽  
En Min Wang ◽  
Jia Zhong Dai ◽  
Bin Jiang Wang ◽  
...  
Keyword(s):  
Growth Hormone ◽  
Blood Glucose ◽  
Gamma Knife ◽  
Pituitary Adenomas ◽  
Gamma Knife Radiosurgery ◽  
Hormonal Control ◽  
High Blood Glucose ◽  
Content Type ◽  
Hormone Levels ◽  
Fine Print

Object. The authors sought to evaluate the effect of gamma knife radiosurgery (GKS) on growth hormone (GH)—producing pituitary adenoma growth and endocrinological response. Methods. From 1993 to 1997, 79 patients with GH-producing pituitary adenomas were treated with GKS. Seventysix patients had acromegaly. Sixty-eight patients were treated with GKS as the primary procedure. The tumor margin was covered with a 50 to 90% isodose and the margin dose was 18 to 35 Gy (mean 31.3 Gy). The dose to the visual pathways was less than 10 Gy except in one case. Sixty-eight patients (86%) were followed for 6 to 52 months. Growth hormone levels declined with improvement in acromegaly in all cases in the first 6 months after GKS. Normalization of the hormone levels was achieved in 23 (40%) of 58 patients who had been followed for 12 months and in 96% of cases for more than 24 months (43 of 45), or more than 36 months (25 of 26), respectively. With the reduction of GH hormone levels, 12 of 21 patients with hyperglycemia regained a normal blood glucose level (p < 0.001). The tumor shrank in 30 (52%) of 58 patients who had been followed for 12 months (p < 0.01), 39 (87%) of 45 patients for more than 2 years (p = 0.02), and 24 (92%) of 26 patients for more than 36 months. In the remainder of patients tumor growth ceased. Conclusions. Gamma knife radiosurgery for GH-producing adenomas showed promising results both in hormonal control and tumor shrinkage. A margin dose of more than 30 Gy would seem to be effective in improving the clinical status, reducing high blood glucose levels, and normalizing hypertension.

Sign in / Sign up

Export Citation Format

Share Document